Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07433023 · ClinicalTrials.gov registry record · Phase 2
tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy
A Phase 2 study, sponsored by Shirley Ryan AbilityLab.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT07433023 is a Phase 2 study that is actively recruiting participants, run by Shirley Ryan AbilityLab. The registered enrollment target is 80 participants.
The verdict
NCT07433023, a Phase 2 study, is actively recruiting participants, sponsored by Shirley Ryan AbilityLab.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
This is an intervention study to investigate the impact of spinal stimulation on mobility outcomes in children with Cerebral Palsy. Participants will complete a 16-week training program with weekly sessions of spinal stimulation and walking or activity-based training. Participants will also have the option to participate in a randomized control trial to investigate the impact of 5-Azacitidine combined with the spinal stimulation to further affect mobility outcomes.
Interventions
- DRUG 5-Azacitidine
- DRUG Mannitol
- OTHER tSCS
- OTHER Functional Activity Training
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-05-28 |
| Est. Completion | 2029-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07433023
The ClinicalTrials.gov registry entry for NCT07433023 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shirley Ryan AbilityLab, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which 5-Azacitidine is the first listed.
NCT07433023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07433023 about?
NCT07433023 is a clinical study titled "tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy". This is an intervention study to investigate the impact of spinal stimulation on mobility outcomes in children with Cerebral Palsy. Participants will complete a 16-week training program with weekly sessions of spinal stimulation and walking or activity-based training. Participants will also have the...
What is the current status of trial NCT07433023?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2026-05-28. Estimated completion is 2029-01-01.
What interventions are being tested in trial NCT07433023?
The interventions under investigation include: 5-Azacitidine (DRUG), Mannitol (DRUG), tSCS (OTHER), Functional Activity Training (OTHER).
Who is sponsoring clinical trial NCT07433023?
This trial is sponsored by Shirley Ryan AbilityLab, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.